# DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

> **NCT03110354** · PHASE1 · TERMINATED · sponsor: **Daiichi Sankyo** · enrollment: 28 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute
- Leukemia, Lymphocytic, Acute

## Interventions

- **DRUG:** DS-3201b

## Key facts

- **NCT ID:** NCT03110354
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-05
- **Primary completion:** 2021-03-09
- **Final completion:** 2021-03-09
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** This study was terminated due to slow accrual.
- **Last updated:** 2024-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03110354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03110354, "DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03110354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*